Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
CRMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.61 - $13.85
Previous CloseN/A
Volume1.29M
Average Volume (3M)760.51K
Market Cap
$653.49M
Enterprise Value$429.83M
Total Cash (Recent Filing)$17.62M
Total Debt (Recent Filing)$6.13M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Mar 25, 2025EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding60,677,204
10 Day Avg. Volume776,698
30 Day Avg. Volume760,511
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)53.99
Price to Cash Flow (P/CF)-12.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.09K
Enterprise Value/Ebitda-9.11
Forecast
1Y Price Target
$16.40Price Target Upside52.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionMultiple label expansion opportunities could at least double DefenCath’s addressable market, with TPN representing at least $150-200M in peak annual sales.
Product AdvancementLead product DefenCath represents a significant advancement in catheter-related bloodstream infection prevention with demonstrated up to ~70% reduction in infection rates, positioning it well to address a critical unmet need in hemodialysis patients.
Revenue GrowthCorMedix’s solid commercial execution helped secure significant contracts with large and medium dialysis organizations, spanning ~60% of US dialysis clinics and including relationships with 4 of the top 5 dialysis providers, which affords significant volume growth potential for DefenCath.
Bears Say
Commercial Execution RisksKey risks to the investment thesis include commercial execution risk in implementing protocols across large dialysis organizations and greater ASP & demand erosion after TDAPA expiry than expected.
Logistical DelaysThere is a delay in ordering from a large dialysis provider, which is logistical and not related to DefenCath.
Price ErosionVolume growth is expected to be partially offset by price erosion due to increased discounting and rebates.
---
Ownership Overview
2.34% Insiders
8.26% Mutual Funds
9.92% Other Institutional Investors
68.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRMD FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was $3.61 and its highest was $13.85 in the past 12 months.
What is Cormedix’s market cap?
Cormedix’s market cap is $653.49M.
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is Mar 25, 2025 which is today.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Oct 30, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.122 by $0.072.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is 0.13.
How many shares outstanding does Cormedix have?
Cormedix has 60,677,204 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.122. Following the earnings report the stock price went down -22.513%.
Which hedge fund is a major shareholder of Cormedix?
Currently, no hedge funds are holding shares in CRMD
---
Cormedix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.40 (52.27% Upside)
$16.40 (52.27% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
174.74%
12-Months-Change
Fundamentals
Return on Equity
-65.04%
Trailing 12-Months
Asset Growth
-15.14%
Trailing 12-Months
Company Description
Cormedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
---
CRMD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call demonstrated strong revenue performance and market penetration of DefenCath, along with positive future EBITDA expectations. However, these positives are counterbalanced by increased operating expenses, potential revenue variability, and high customer concentration. Overall, the call reflects a cautiously optimistic outlook with significant achievements and some areas of concern.Read More>---
CRMD Stock 12 Month Forecast
Average Price Target
$16.40
▲(52.27% Upside)
Technical Analysis
Best Analysts Covering CRMD
1 Year
1 Year Success Rate
8/9 ratings generated profit
1 Year Average Return
+100.30%
reiterated a buy rating 9 days ago
Copying Les Sulewski's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +100.30% per trade.
---